Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
The latest announcement is out from Immatics ( (IMTX) ).
On June 2, 2025, Immatics N.V. announced the convening of its annual general meeting, scheduled for June 18, 2025, in Amsterdam, Netherlands. This meeting will allow shareholders to discuss and vote on various company matters, reflecting Immatics’ commitment to maintaining transparency and active shareholder engagement. The announcement underscores the company’s ongoing efforts to align its governance practices with shareholder interests, potentially impacting its strategic direction and stakeholder relations.
The most recent analyst rating on (IMTX) stock is a Buy with a $20.00 price target. To see the full list of analyst forecasts on Immatics stock, see the IMTX Stock Forecast page.
Spark’s Take on IMTX Stock
According to Spark, TipRanks’ AI Analyst, IMTX is a Neutral.
Immatics’ stock score is influenced by strong revenue growth but offset by profitability and cash flow challenges. Technical analysis suggests moderate short-term bullish momentum, though longer-term trends remain bearish. Valuation struggles with a negative P/E ratio, common in the biotech industry.
To see Spark’s full report on IMTX stock, click here.
More about Immatics
Immatics N.V. is a biotechnology company based in Tübingen, Germany, focusing on the development of T-cell receptor-based cancer immunotherapies. The company operates within the biopharmaceutical industry, aiming to deliver innovative treatments for cancer patients by leveraging its proprietary technology platforms.
Average Trading Volume: 658,755
Technical Sentiment Signal: Sell
Current Market Cap: $655.2M
For detailed information about IMTX stock, go to TipRanks’ Stock Analysis page.